Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR... von Lawitz, Eric, Prof, Poordad, Fred F, Prof, Pang, Phillip S, MD, Hyland, Robert H, DPhil, Ding, Xiao, PhD, Mo, Hongmei, PhD, Symonds, William T, PharmD, McHutchison, John G, MD, Membreno, Fernando E, MD

Volltext

Hepatitis C virus drug resistance–associated substitutions: State of the art summary von Lontok, Erik, Harrington, Patrick, Howe, Anita, Kieffer, Tara, Lennerstrand, Johan, Lenz, Oliver, McPhee, Fiona, Mo, Hongmei, Parkin, Neil, Pilot‐Matias, Tami, Miller, Veronica

Volltext

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials von Svarovskaia, Evguenia S., Dvory-Sobol, Hadas, Parkin, Neil, Hebner, Christy, Gontcharova, Viktoria, Martin, Ross, Ouyang, Wen, Han, Bin, Xu, Simin, Ku, Karin, Chiu, Sophia, Gane, Edward, Jacobson, Ira M., Nelson, David R., Lawitz, Eric, Wyles, David L., Bekele, Neby, Brainard, Diana, Symonds, William T., McHutchison, John G., Miller, Michael D., Mo, Hongmei

Volltext

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an... von Mizokami, Masashi, Prof, Yokosuka, Osamu, Prof, Takehara, Tetsuo, Prof, Sakamoto, Naoya, Prof, Korenaga, Masaaki, MD, Mochizuki, Hitoshi, MD, Nakane, Kunio, MD, Enomoto, Hirayuki, MD, Ikeda, Fusao, MD, Yanase, Mikio, MD, Toyoda, Hidenori, MD, Genda, Takuya, MD, Umemura, Takeji, MD, Yatsuhashi, Hiroshi, Prof, Ide, Tatsuya, MD, Toda, Nobuo, MD, Nirei, Kazushige, Ueno, Yoshiyuki, Prof, Nishigaki, Yoichi, MD, Betular, Juan, BS, Gao, Bing, PhD, Ishizaki, Akinobu, BA, Omote, Masa, PhD, Mo, Hongmei, MD, Garrison, Kim, PhD, Pang, Phillip S, MD, Knox, Steven J, BS, Symonds, William T, PharmD, McHutchison, John G, MD, Izumi, Namiki, Prof, Omata, Masao, Prof

Volltext

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, doubl... von Lawitz, Eric, Prof, Lalezari, Jay P, MD, Hassanein, Tarek, Prof, Kowdley, Kris V, Prof, Poordad, Fred F, Prof, Sheikh, Aasim M, MBBS, Afdhal, Nezam H, Prof, Bernstein, David E, Prof, DeJesus, Edwin, MD, Freilich, Bradley, MD, Nelson, David R, Prof, Dieterich, Douglas T, Prof, Jacobson, Ira M, Prof, Jensen, Donald, Prof, Abrams, Gary A, MD, Darling, Jama M, MD, Rodriguez-Torres, Maribel, MD, Reddy, K Rajender, Prof, Sulkowski, Mark S, Prof, Bzowej, Natalie H, MD, Hyland, Robert H, DPhil, Mo, Hongmei, PhD, Lin, Ming, PhD, Mader, Michael, MS, Hindes, Robert, MD, Albanis, Efsevia, MD, Symonds, William T, PharmD, Berrey, Michelle M, MD, Muir, Andrew, Prof

Volltext

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein von Lawitz, Eric J, Dvory-Sobol, Hadas, Doehle, Brian P, Worth, Angela S, McNally, John, Brainard, Diana M, Link, John O, Miller, Michael D, Mo, Hongmei

Volltext

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C von Lawitz, Eric J, Gruener, Daniel, Hill, John M, Marbury, Thomas, Moorehead, Lisa, Mathias, Anita, Cheng, Guofeng, Link, John O, Wong, Kelly A, Mo, Hongmei, McHutchison, John G, Brainard, Diana M

Volltext

The effects of postoperative targeted immunotherapy on peripheral blood cytokines and immune cell profile in lung cancer patients von Zhang, Chuang, Mo, Hongmei, Li, Min, Wang, Shuaiyan, Dou, Xiaowen, Zhang, Xiuming

Volltext

Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir von Wyles, David, Dvory-Sobol, Hadas, Svarovskaia, Evguenia S, Doehle, Brian P, Martin, Ross, Afdhal, Nezam H, Kowdley, Kris V, Lawitz, Eric, Brainard, Diana M, Miller, Michael D, Mo, Hongmei, Gane, Edward J

Volltext

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study von Abergel, Armand, Prof, Asselah, Tarik, Prof, Metivier, Sophie, MD, Kersey, Kathryn, MSc, Jiang, Deyuan, PhD, Mo, Hongmei, MD, Pang, Phillip S, MD, Samuel, Didier, MD, Loustaud-Ratti, Véronique, Prof

Volltext

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions von Svarovskaia, Evguenia S., Gane, Edward, Dvory-Sobol, Hadas, Martin, Ross, Doehle, Brian, Hedskog, Charlotte, Jacobson, Ira M., Nelson, David R., Lawitz, Eric, Brainard, Diana M., McHutchison, John G., Miller, Michael D., Mo, Hongmei

Volltext

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885 von Wong, Kelly A, Worth, Angela, Martin, Ross, Svarovskaia, Evguenia, Brainard, Diana M, Lawitz, Eric, Miller, Michael D, Mo, Hongmei

Volltext

Sofosbuvir susceptibility of genotype 1 to 6 HCV from DAA-naïve subjects von Han, Bin, Martin, Ross, Xu, Simin, Parvangada, Aiyappa, Svarovskaia, Evguenia S., Mo, Hongmei, Dvory-Sobol, Hadas

Volltext

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance von Powdrill, Megan H, Tchesnokov, Egor P, Kozak, Robert A, Russell, Rodney S, Martin, Ross, Svarovskaia, Evguenia S, Mo, Hongmei, Kouyos, Roger D, Götte, Matthias

Volltext

Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes von Chaturvedi, Nimisha, Svarovskaia, Evguenia S, Mo, Hongmei, Osinusi, Anu O, Brainard, Diana M, Subramanian, G Mani, McHutchison, John G, Zeuzem, Stefan, Fellay, Jacques

Volltext

Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin von Hedskog, Charlotte, Doehle, Brian, Chodavarapu, Krishna, Gontcharova, Viktoria, Crespo Garcia, Javier, De Knegt, Robert, Drenth, Joost P.H, McHutchison, John G., Brainard, Diana, Stamm, Luisa M., Miller, Michael D., Svarovskaia, Evguenia, Mo, Hongmei

Volltext

In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6 von Dvory‐Sobol, Hadas, Han, Bin, Lu, Julia, Yu, Mei, Beran, Rudolf K., Cheng, Guofeng, Martin, Ross, Svarovskaia, Evguenia, Mo, Hongmei

Volltext

Abundant Drug-Resistant NS3 Mutants Detected by Deep Sequencing in Hepatitis C Virus-Infected Patients Undergoing NS3 Protease Inhibitor Monotherapy von Svarovskaia, Evguenia S, Martin, Ross, McHutchison, John G, Miller, Michael D, Mo, Hongmei

Volltext

Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis von Uchida, Yoshihito, Nakamura, Shugo, Kouyama, Jun-Ichi, Naiki, Kayoko, Motoya, Daisuke, Sugawara, Kayoko, Inao, Mie, Imai, Yukinori, Nakayama, Nobuaki, Tomiya, Tomoaki, Hedskog, Charlotte, Brainard, Diana, Mo, Hongmei, Mochida, Satoshi

Volltext

Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia von Isakov, Vasily, Hedskog, Charlotte, Wertheim, Joel O., Hostager, Reilly E., Parhy, Bandita, Schneider, Adriano De Bernardi, Suri, Vithika, Mo, Hongmei, Geivandova, Natalia, Morozov, Vyacheslav, Bessonova, Elena, Gankina, Natalya, Zhdanov, Konstantin, Abdurakhmanov, Dzhamal, Svarovskaia, Evguenia

Volltext